



K.T. 2/15

PATENT

ATTORNEY DOCKET NO.: 29924/980570

RECEIVED

FEB 13 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Chen et al.

) I hereby certify that this paper is being
TECH CENTER 1600/2900
deposited with the United States Postal
Service as first class mail, postage prepaid,
in an envelope addressed to: Commissioner
for Patents Washington, D.C. 20231, on
this date:

Serial No: 09/541,848

) Service as first class mail, postage prepaid,
) in an envelope addressed to: Commissioner
) for Patents Washington, D.C. 20231, on
) this date:

Filed: April 3, 2000

) for Patents Washington, D.C. 20231, on
) this date:

For: MDM2-SPECIFIC
ANTISENSE
OLIGONUCLEOTI

RECEIVED
FEB 06 2001
January 31, 2001

Art Unit: 1635

) David W. Clough

Examiner: Andrew Wang

Reg. No.: 36,10/
Attorney for Applicants

**AMENDMENT AND RESPONSE TO NOTICE TO COMPLY WITH
SUBMISSION OF SUBSTITUTE SEQUENCE LISTING AND
STATEMENT UNDER 37 C.F.R. §1.825 (a) & (b)**

Commissioner for Patents
Washington, DC 20231

Siri:

This is in response to a Notice to Comply mailed November 1, 2000 (copy enclosed) in which the Patent Office indicated that the above-identified application failed to comply with one or more of the requirements of 37 C.F.R. §§ 1.821-1.825, pertaining to Sequence Listings. Enclosed with this response to a Notice to Comply is a Petition for Extension of Time Under 37 C.R.F. 1.136(a) and fee pursuant to 37 C.F.R. 1.17(a).

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: _____

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE